Transplantatie en cellulaire therapie
Pediatric subjects with chronic Graft Versus Host
Disease. Ibrutinib (PCYC-1146-IM)
Patients less than 18 years of age with histologically BIANCA
confirmed B-cell NHL who have relapsed after
one or more prior therapies or are primary refractory.
Pediatric HSCT recipients transplanted from a Tracing HSCs after transplantation
sibling donor, with >95% donor chimerism and
without major HSCT-related complications.
Tisagenlecleucel (Kymriah ®) as standard of care Tisagenlecleucel
Patients 12-65 years of age with a diagnosis of NiCord III
hematological malignancy who are candidates
for unrelated cord blood transplantation, with
qualifying HLA-matched UCB units with sufficient
pre-cryopreserved total nucleated cell dose and
CD34+ cell dose (see protocol for further specs)
Pediatric patients (0-18 years old) receiving a
non-T-cell depleted allogeneic hematopoietic (gesloten voor inclusie)
cell transplantation with Thymoglobulin in the
conditioning regimen as standard of care.